Brazil Advances Its First Fully Domestic mRNA Vaccine Toward Clinical Trials
Brazil is making progress in developing its own messenger RNA vaccine technology, with the country’s first fully domestically developed mRNA vaccine moving toward clinical trials.
The Brazilian Ministry of Health announced that the vaccine platform has reached an important stage as the country works to strengthen its scientific and manufacturing capacity and reduce dependence on foreign health technologies.
Government Invests in mRNA Technology
Brazil’s Ministry of Health has invested R$210 million in the development of national messenger RNA platforms.
The programme brings together three major Brazilian centres: Fiocruz, the Butantan Institute and the UFMG Vaccine Competence Centre. The government says the investment is intended to establish a national technological base capable of producing vaccines and other strategic health products.
First Vaccine Targets COVID-19
The first vaccine developed through the national mRNA platform is designed to target COVID-19.
Fiocruz’s Bio-Manguinhos is preparing to begin clinical studies of the vaccine, which was developed using a Brazilian mRNA platform. The clinical study has been authorised by Brazil’s health regulator, Anvisa, and will evaluate the vaccine as a booster dose under the country’s current immunisation strategy.
Three National Centres Involved
The Brazilian programme is designed to develop more than one vaccine. It is creating infrastructure that could eventually support the development of different vaccines and health products needed by Brazil’s public health system.
Under the government’s New PAC Health programme, R$77 million was allocated to Fiocruz’s mRNA platform, R$73 million to Butantan and R$60 million to the UFMG Vaccine Competence Centre.
Reducing Dependence on Foreign Technology
Brazil says the initiative is part of a broader strategy to strengthen its health-industrial complex and reduce reliance on imported technologies.
Developing domestic mRNA capabilities could give Brazil greater flexibility when responding to future health emergencies and could shorten the country’s dependence on external suppliers for advanced vaccine technologies.
Potential Beyond COVID-19
The government views the programme as a long-term technological investment rather than a project limited to a single vaccine.
Once the national platform is established, researchers could potentially adapt the technology for other infectious diseases and health challenges, providing Brazil with a stronger domestic foundation for vaccine development.
What Happens Next?
The COVID-19 mRNA vaccine will now move into clinical evaluation, where researchers will assess its performance and safety according to regulatory requirements.
The development marks an important step in Brazil’s effort to build advanced vaccine technology domestically and strengthen its ability to respond to future public-health emergencies.
